Aquestive Therapeutics
AQST
121 hedge funds and large institutions have $131M invested in Aquestive Therapeutics in 2025 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 19 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
6% more funds holding
Funds holding: 114 → 121 (+7)
2.82% less ownership
Funds ownership: 47.57% → 44.76% (-2.8%)
15% less capital invested
Capital invested by funds: $154M → $131M (-$23.6M)
58% less call options, than puts
Call options by funds: $391K | Put options by funds: $923K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$11.3M |
| 2 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$2.45M |
| 3 |
Morgan Stanley
New York
|
+$2.39M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.94M |
| 5 |
Two Sigma Advisers
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$9.36M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$7.6M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.74M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$2.22M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$827K |
AQST Hedge Fund Activity: Q1 2025 in Review
121 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2025, worth a combined $131M — down 15% from $154M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AQST positions and 19 closed out — a net gain of 8 holders — while 46 added to existing stakes and 29 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $11.3M. The largest seller was VR Adviser, exiting entirely with an estimated $9.36M sold.
- 121 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2025, up from 114 in Q4 2024.
- Funds reported $131M of Aquestive Therapeutics stock for Q1 2025, down 15% quarter-over-quarter.
- 27 funds opened new Aquestive Therapeutics positions in Q1 2025 and 19 closed out, a net change of +8 holders.
- The largest Aquestive Therapeutics buyer in Q1 2025 was Perceptive Advisors, an estimated $11.3M added.
- The largest Aquestive Therapeutics seller in Q1 2025 was VR Adviser, an estimated $9.36M sold.
Based on aggregated 13F filings for Q1 2025.